"All adults who wish will be vaccinated by the end of the summer."
This promise by Emmanuel Macron should in all likelihood be kept, despite the serious side effects and the delays that accumulate in deliveries.
The latest difficulty, on Tuesday April 13, the American pharmaceutical group Johnson & Johnson delayed the deployment in Europe of its single-dose vaccine developed by its Belgian subsidiary Janssen.
The announcement follows US health officials' decision to suspend its use in the United States, after six severe cases of blood clots were detected out of 6.8 million injections.
Adverse effects very similar to those seen very rarely following injections of the AstraZeneca vaccine.
Both are based on the use of a viral vector, an adenovirus.
France reserves the Anglo-Swedish vaccine for over 55s, a group for which the benefit / risk balance remains extremely favorable.
To discover
Covid-19: instructions for use of self-tests
Read also:
Covid-19: should vaccination be extended to “essential” professions?
"
These restrictions
This article is for subscribers only.
You have 75% left to discover.
Subscribe: 1 € the first month
Can be canceled at any time
I ENJOY IT
Already subscribed?
Log in